See beyond appearances

1 in 3 cancers is a skin cancer

Skin cancer is the most commonly occurring cancer in humans, with an incidence that has steadily increased worldwide. The prognosis of advanced melanoma is poor, and carcinomas are associated with high morbidity.        

60% biopsies result in benign diagnoses

Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed (link).

20% skin cancers missed at early stage

Dermoscopy improves the diagnostic accuracy for melanoma but only for experienced examiners. Dermoscopy by untrained or less experienced examiners is no better than clinical inspection without dermoscopy (link).

Discover deepLive™

DAMAE Medical develops deepLive™ medical device, the new best-in-class imaging system pairing penetration and cellular resolution in 3D. deepLive™ is adapted to the imaging of multiple skin conditions, promoting efficient, reassuring and non-invasive patient management.


Based on LC-OCT™ innovative technology

deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography) technology which provides a unique 3D imaging modality, allowing the user to   switch from a histology-like vertical mode to a confocal-like horizontal mode,
and to record a 3D stack of tissue volumes in situ. 

  • Image

Navigations in LC-OCT™ 3D stacks


LC-OCT™ imaging of the back of a hand


LC-OCT™ imaging of a fingerprint

User Testimonial

Prof. Mariano Suppa from the Dermatology Department of the Erasme Hospital, ULB Brussels, shares his experience with deepLive™.

  • Image

Quantitative skin analyses
adapted to your studies

  • Image

    Skin Surface 3D segmentation

  • Image

    Dermo-Epidermal Junction 3D segmentation

  • Image

    Keratinocytes distribution

  • Image

    Keratinocytes density with depth

  • Image

    Collagen fibers segmentation

Our company


> Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO) who filed the patent protecting LC-OCT's technology 

> Proof of concept of LC-OCT vertical imaging


> First LC-OCT images performed on fresh biopsies of suspected skin cancer

> Validation of the potential of LC-OCT vertical imaging for the 2 main types of skin cancer: carcinoma and melanoma


> First clinical demonstrator installed at the Saint-Etienne University Hospital

> Winner of the Digital Innovation Competition organized by Bpifrance

> Signature of the exclusive license agreement for LC-OCT technology


> Closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors

> First proof of concept of LC-OCT 3D & obtaining ISO 13485 certificate


> Winner of the World Competition of Innovation organized by Bpifrance

> First scientific publication: A. Dubois and al., “LC-OCT for high-resolution noninvasive imaging of skin tumors”, JBO 23, 106007


> Miniaturized LC-OCT 3D in a handheld probe
> Manufacturing of 10 LC-OCT 3D devices

> Launch of clinical validation of LC-OCT 3D


> Integration of the live dermoscopic camera inside the handheld probe
> Obtaining CE mark Class I for deepLive™

> Commercial launch of deepLive™ in Europe


> Manufacturing of first series

> Implementation of a scalable production strategy with industrial partners

> Closing of €5 million investment led by BNP Paribas Development


> Presentation retrospective study on BCC Diagnostic Performance by Prof. Suppa

> Funding of ECOBASO, a large randomized, prospective, multi-center clinical trial 


> deepLive™ receives CE Mark Class IIA under EU MDR 2017/745

> Publication of the 80th scientific paper on LC-OCT technology and usages 

> 40 centers installed in more than 10 countries 


Prof. Arnaud Duboispresents LC-OCT technology


3 key numbers in the development of DAMAE Medical

Latest News

March 2023
deepLive™ receives CE Mark Class IIA under EU MDR 2017/745
Read More
February 2022
Damae Medical raises €5M in Series A Financing
Read More
September 2019
DAMAE Medical receives €2.4 million from European Union’s Horizon 2020 
Read More

Contact us

DAMAE Medical
14 rue Sthrau
75013 Paris

P: +33 1 44 49 04 10

If you are looking for a position or an internship, send your CV to
We will get back to you as soon as possible.